AgomAb Therapeutics
- Biotech or pharma, therapeutic R&D
AgomAb is developing small molecule ALK-5 inhibitors (TGFb pathway) for Fibrostenosing Crohn's Disease (FSCD) and Idiopathic Pulmonary Fibrosis (IPF) and hepatocyte growth factor (HGF) mimetic antibodies for the regeneration of damaged tissues to treat compensated liver cirrhosis patients.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}